Viewpoint Molecular Targeting, Inc.

Coralville, IA Part of Perspective Therapeutics, Inc.

UEI
RDZCK3F6AU73
CAGE
5HQZ4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
2500 Crosspark Rd e116, Coralville, IA 52241, USA
Founded
2023
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
"systemic targeted radionuclide therapy for metastatic melanoma" HHSN261201700036C National Cancer Institute (NIH) $1,944,651
Sbir phase I-radionuclide therapy for metastatic melanoma viewpoint molecular targeting, LLC:1256544 [15-068338] HHSN261201500069C National Cancer Institute (NIH) $298,184

Grant awards

Award Agency Obligated Awarded
Antibody-based prertargeted alpha particle therapy for ovarian cancer R42CA287696 National Cancer Institute (NIH) $377,854
Image-guided dosimetry-based alpha particle therapy for neuroblastoma. - significance: neuroblastoma is the most common… R44CA268314 National Cancer Institute (NIH) $3,932,125
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for… R44CA250872 National Cancer Institute (NIH) $3,993,602
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for PB-212… R44CA254613 National Cancer Institute (NIH) $3,999,532
Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic… R44CA232954 National Cancer Institute (NIH) $2,901,435

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
The Research Foundation For The State University Of New York Radiotheranostic host-guest pretargeting with Pb-203 and Pb-212 R37CA282650 $15,988
The Research Foundation For The State University Of New York Radiotheranostic host-guest pretargeting with Pb-203 and Pb-212 R37CA282650 $72,901
Research Institute At Nationwide Children's Hospital Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors R01CA291827 $71,196

Similar vendors

Vendor Location Primary NAICS
Senex Biotechnology Inc. UEI G8XKMW3DYMQ6 Maynard, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Athna Biotech Inc. UEI LBCCTS71U2N4 Watkinsville, GA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Nanocan Therapeutics Corporation UEI MUW6XWEVLLN3 Forest Heights, MD 541713 Research and Development in Nanotechnology
Oncotab, Inc. UEI E5FXNY7GG5M5 Charlotte, NC 541714 Research and Development in Biotechnology (except Nanobiotechnology)
PDX Pharmaceuticals Inc. UEI VTX7JRKLC3F5 Portland, OR 541713 Research and Development in Nanotechnology

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Viewpoint Molecular Targeting, Inc. is a corporate entity registered in SAM.gov since 2009, located in Coralville, Iowa. The company appears to be a biotechnology research organization focused on developing targeted alpha-particle therapies for various cancer treatments. While specific details about the company's comprehensive background are not provided, its federal grant history indicates a specialized focus on innovative cancer therapy research and development, particularly in the domain of precision oncological interventions.

The company has received multiple federal grant awards from the National Cancer Institute (NCI) through Project Grant mechanisms, consistently targeting advanced cancer treatment technologies. These grants, each approximately $300,000-$400,000, have supported research into image-guided alpha-particle therapies for specific cancer types, including high-grade serous ovarian carcinoma (HGSOC), neuroblastoma, neuroendocrine tumors, and metastatic melanoma. The research involves developing sophisticated therapeutic approaches such as antibody-based pretargeting strategies, radionuclide production technologies, and innovative molecular targeting techniques. Each grant has focused on different aspects of therapeutic development, including validating monoclonal antibodies, optimizing radioligand formulations, conducting preclinical pharmacology and toxicology studies, and establishing protocols for potential future clinical trials. The company's work appears aimed at creating more precise, targeted cancer treatments that can potentially improve patient outcomes in cancers with historically poor prognoses.

Quick answers

Is Viewpoint Molecular Targeting, Inc. registered in SAM.gov?

Yes. Viewpoint Molecular Targeting, Inc.'s SAM.gov registration is active through August 13, 2027.

What is Viewpoint Molecular Targeting, Inc.'s CAGE code?

Viewpoint Molecular Targeting, Inc.'s CAGE code is 5HQZ4, and its Unique Entity ID (UEI) is RDZCK3F6AU73.

What is Viewpoint Molecular Targeting, Inc.'s most recent federal award?

Viewpoint Molecular Targeting, Inc.'s most recent federal grant award is Antibody-based prertargeted alpha particle therapy for ovarian cancer (R42CA287696), from National Cancer Institute (NIH), on June 5, 2024.

On GovTribe

See Viewpoint Molecular Targeting, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe